首页CYBN • NYSEAMERICAN
add
Cybin Inc
市场资讯
财务信息
损益表
收入
净收入
| (CAD) | 2024年12月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 3133.20万 | 15.94% |
净收入 | -1054.20万 | 65.24% |
净利润率 | — | — |
每股收益 | -0.53 | 84.50% |
息税折旧摊销前利润 | -3127.90万 | -16.41% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (CAD) | 2024年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.36亿 | 249.47% |
总资产 | 2.54亿 | 95.45% |
负债总额 | 1330.60万 | 56.49% |
权益总额 | 2.40亿 | — |
发行在外的股份 | 2103.59万 | — |
市净率 | 0.64 | — |
资产回报率 | -30.36% | — |
资本回报率 | -31.62% | — |
现金流
现金净变动
| (CAD) | 2024年12月info | 年同比变化 |
|---|---|---|
净收入 | -1054.20万 | 65.24% |
来自运营的现金 | -2712.40万 | -4.15% |
投资现金 | -30.30万 | -104.06% |
融资现金 | -17.90万 | -100.45% |
现金净变动 | -1802.80万 | -186.34% |
自由现金流 | -1733.55万 | -88.49% |
简介
Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, CYB002, CYB003, CYB004, CYB005, and CYB006. Another drug that the company has developed is CYB210010.
As of January 2025, CYB003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. Wikipedia
CEO
成立时间
2019
员工数量
50
